Comment from ASA-DahShu IDSWG Master Protocol multidisciplinary Working Group

Summary: The commenter, likely a pharmaceutical or clinical research company, provides specific technical feedback on the draft guidance for master protocols. They suggest clarifying language regarding randomization ratios, informed consent procedures for platform trials, and the distinction between sub-study and overarching protocol amendments to improve practical feasibility and patient experience.